Pole de Pharmacologie et Thérapeutique (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, B01.5309, Avenue Mounier 52, 1200, Brussels, Belgium.
Curr Hypertens Rep. 2012 Aug;14(4):310-7. doi: 10.1007/s11906-012-0278-3.
Beta-blockers are widely prescribed for the treatment of a variety of cardiovascular pathologies. Compared to traditional beta-adrenergic antagonists, beta-blockers of the new generation exhibit ancillary properties such as vasodilation through different mechanisms. This translates into a more favorable hemodynamic profile. The relative affinities of beta-adrenoreceptor antagonists towards the three beta-adrenoreceptor isotypes matter for predicting their functional impact on vasomotor control. This review will focus on the mechanisms underlying beta-blocker-evoked vasorelaxation with a specific emphasis on agonist properties of beta(3)-adrenergic receptors.
β受体阻滞剂被广泛用于治疗各种心血管疾病。与传统的β肾上腺素能拮抗剂相比,新一代的β受体阻滞剂通过不同的机制具有血管扩张等附加特性。这转化为更有利的血液动力学特征。β肾上腺素能受体拮抗剂对三种β肾上腺素能受体亚型的相对亲和力对于预测其对血管运动控制的功能影响很重要。这篇综述将重点介绍β受体阻滞剂引起的血管舒张的机制,并特别强调β 3 肾上腺素能受体的激动剂特性。